The Princess Máxima Center for Pediatric Oncology is a new research hospital concentrating healthcare, research and education with regard to cancer in children in a single location in Utrecht. The institute aims to provide the highest level of care for all children with cancer, with optimal quality of life. The center brings together the best possible care and scientific research, creating a unique interdisciplinary institute for pediatric oncology in Europe.
The Tytgat Group is looking for an enthusiastic, highly motivated postdoctoral researcher with interest in translational liquid biopsy sequencing studies in pediatric solid tumors.
The Tytgat Group
The overall aim of our group is to translate basic findings to the clinic. With respect to liquid biopsies, we study the clinical efficacy to use also liquid biopsies to assist at diagnosis, the potential to use these to measure response to therapy, detect resistant and progressive disease, clonal heterogeneity and early recurrence. The Tytgat group has active projects on liquid biopsies in Neuroblastoma, Rhabdomyosarcoma and pediatric renal tumors ongoing in the Princess Máxima Center for Pediatric Oncology, the Dutch national hospital for childhood cancer. This institute has the ambition to cure every child with cancer, while providing optimal quality of life. Hereto, scientific research and clinical care are closely integrated, providing a unique opportunity for translational research. In our group, we apply innovative single-cell technology to samples of pediatric patients. We collaborate closely with disease-oriented groups within the Princess Máxima Center and internationally with other groups studying liquid biopsies in pediatric solid tumors. Core values in our group are collaboration, curiosity and clinical impact.
Research Project: Molecular analysis of circulating tumor-derived nucleic acids in children with solid tumors. The presence of circulating cell-free DNA (cfDNA) and cell-free RNA (cfRNA) has been demonstrated in various types of body fluids, including peripheral blood (PB), bone marrow (BM), cerebrospinal fluid (CSF), urine, and saliva. The fraction of tumor specific cfDNA i.e., circulating (cell-free) tumor DNA (ctDNA), derives from the primary tumor and metastases, resolving potential molecular tumor heterogeneity and can be studied to identify tumor derived mutations, copy number alterations and methylation patterns. In this project, different sequencing approaches of cfDNA will be set up, starting with whole exome sequencing of cfDNA, performed on liquid biopsies from patients with various solid tumors. The primary tumor will be sequenced in clinical care. As the bio-informatic pipeline is also to be set up in this project, affinity with bio-informatics can be considered a benefit.
- PhD degree in biomedical sciences, molecular/cellular biology, or an equivalent thereof, and a clear experience in sequencing and potentially affinity with bio-informatics
- It is important that the candidate has a proven affinity with translational research
- Pioneer, who is willing to contribute to the development of a liquid biopsy sequencing pipeline
- Team player who is willing to collaborate closely with scientists and clinicians, nationally and internationally
- Excellent communication and presentation skills
- Ambition to pursuit a career in science
- The post-doc will be the center of the Tytgat group liquid biopsy projects and will also coordinate these and work closely with PhD students
We offer a challenging position in an international, multidisciplinary research environment, which combines clinical oncology, biology and cfDNA sequencing.
The position is based on 32 – 36 hours per week. You will start on a temporary position for the duration of one year, which –upon satisfactory completion of the first year- will be extended for a total of four years. Salary is based on postdoc salary FWG 60 depending on years of experience. The Princess Máxima Center operates according to the collective labor agreement ‘cao algemene ziekenhuizen’.
Apply for this position?
You can apply for this position until March 5th 2021 by pressing the orange “Solliciteer direct”“ button on this screen.
Contact and application
For more information about the vacancy, you are welcome to contact Dr. Lieve Tytgat (firstname.lastname@example.org).
Acquisitie naar aanleiding van deze vacature wordt niet op prijs gesteld.Solliciteer direct